Karling Alice Leung
No más puestos en curso
Perfil
Karling Alice Leung served as President & Chief Executive Officer at Intarcia Therapeutics, Inc. from 2004 to 2011.
Prior to that, she held positions as VP-Worldwide Licensing & External Development at Bristol Myers Squibb Co., Principal at Bayer Schering Pharma AG, and Vice President & General Manager at Berlex Pharmaceuticals, Inc. Leung holds an MBA from Cornell University and an undergraduate degree from the University of Western Ontario.
Antiguos cargos conocidos de Karling Alice Leung.
| Empresas | Cargo | Fin |
|---|---|---|
| Bayer Schering Pharma AG | Corporate Officer/Principal | - |
| Berlex Pharmaceuticals, Inc. | Corporate Officer/Principal | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Presidente | - |
Formación de Karling Alice Leung.
| Cornell University | Masters Business Admin |
| University of Western Ontario | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Empresas privadas | 3 |
|---|---|
| Bayer Schering Pharma AG | Health Technology |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
| Berlex Pharmaceuticals, Inc. |
- Bolsa de valores
- Insiders
- Karling Alice Leung
